RT Journal Article
SR Electronic
T1 Lung cancer screening: What has changed and what can we learn from it?
JF The Annals of Family Medicine
JO Ann Fam Med
FD American Academy of Family Physicians
SP 2595
DO 10.1370/afm.20.s1.2595
VO 20
IS Supplement 1
A1 Au, Zachary
A1 Go, Camille
YR 2022
UL http://www.annfammed.org/content/20/Supplement_1/2595.abstract
AB Lung cancer, predominantly caused by smoking, has consistently been one of the leading causes of cancer-related deaths in the United States. The United States Preventive Services Task Force (USPSTF) recommended screening with low-dose CT scan (LDCT) to reduce overall mortality. Throughout the years, significant changes have been made by the USPSTF after the National Lung Screening Trial (NLST) found a significant 20% relative reduction in lung cancer mortality. The 2021 USPSTF recommendation now includes expanded access to this screening, including lowering the screening age from 55 to 50, as well as recommending to expand access to females and underserved populations. Although these are noteworthy changes, there are still concerns that these new criteria do not take into account race, sex and younger patients who smoke >20-pack years. Given the prevalence of vaping and “e-cigarette”, we recommend that providers be vigilant to identify eligible populations who may benefit from this screening, with the discussion of its risks and benefits. Counseling, encouraging smoking cessation and early screening protocols should still be key factors preventing lung cancer. It is also important to lobby for broader changes to current recommendations to adapt to the current smoking culture of society.